Buy Laurus Labs: target of Rs 735: Sharekhan
Sharekhan is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 735 in its research report dated April 29, 2022.30-04-2022
30-04-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of the Q4 & Full Year FY22 Results conference call hosted on April 29, 202229-04-2022
Earnings Call for Q4FY22 of Laurus Labs
Conference Call with Laurus Labs Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.29-04-2022
Laurus Labs Ltd - 540222 - Change In Time Of The 171H Annual General Meeting Of The Company To Be Held On June 30, 2022
This is to inform all the Stakeholders of the Company that the time of 17th Annual General Meeting of the Company which was erroneously shown as 03.00 PM (IST) on June 30, 2022 may be read as 04.00 PM (1ST). Except for above, there are no changes in any other information declared earlier. Kindly take note of the same.28-04-2022
Q4FY22 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals firm Laurus Labs declares Q4FY22 result: Laurus Labs generates Revenue of Rs 4,936 Cr and EBITDA margins of 29% for FY 22 FY22: Revenue at Rs 4,936 crs, up 3 % (YoY) EBITDA Rs 1,436 crs, decreased by 9 % (YoY) EBITDA margins at 29 % PAT at Rs 828 crs, decreased by 16 % (YoY) PAT margins at 17 % EPS (Diluted) (face value of Rs 2/-) for the period at Rs 15.4 per share Q4 FY22: Total net revenue Rs 1,425 crs, increased 1 % (YoY) EBITDA Rs 398 crs, decreased by 17 % (YoY) EBITDA margins at 28 % PAT at Rs 230 crs, decreased by 23 % (YoY) PAT margins at 16 % (YoY) EPS (Diluted) for the period at Rs 4.3 per share (not annualised) Interim Dividend of INR 1.20/- per share. Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “Our FY22 results reflects fairly strong operational resilience overall with better mix and sustained profitability despite transient headwinds in our ARV API business and disruption in supply chain. We have continued to significantly built on manufacturing and R&D; capabilities and accelerating efficiencies to enhance our strategic value proposition which should reflect in our performance in coming years. Sequentially, Our Q4 results have improved substantially on revenue across key business verticals. Growth in ARV APIs and formulations have started to rebound and our CDMO-synthesis business continued to deliver solid performance both for the quarter and FY22 clocking 105% and 77% growth. During the year, we have brought new capacity on line and adding more capacities in high growth therapeutics which should support API business (ex-ARV) returning to growth trajectory. We would continue to fortify resilience with focus to deliver long term sustainable growth” Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said; “Even as the world continued to face unprecedented challenges in the business environment, We have delivered sustained FY22 results overall. Our Revenues have grown 3% to Rs 4,936 crs, driven by impressive growth in CDMO business, and healthy FDF performance. EBITDA came at Rs 1,436 crs with sustained EBITDA margins of 29% as better mix offset negative operating leverage. We continue to advance on key capex projects and Debt leverage position remains comfortable. On QoQ basis our Q4 results were encouraging, Revenue increased by 38% to Rs 1,425 crs. EBITDA was up by 37% to Rs 398 crs and EBITDA margins stood healthy at 28%.” Result PDF28-04-2022
Laurus Labs Ltd - 540222 - Corporate Action-Fixes Book Closure Date For AGM
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, this is to inform you that the Register of Members and Share Transfer Books of the Company will remain closed from June 24, 2022 to June 30, 2022 (both days inclusive) for the purpose of 17th Annual General Meeting. The next Annual General Meeting of the Cotnpany shall be held on Thursday, June 30, 2022 at 3.00 pm through Video Conferencing or Other Audio-Visual Means (OVAM) as per the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.28-04-2022
Laurus Labs Ltd - 540222 - Corporate Action-Board approves Dividend
The Board of Directors of the Company in their meeting held on April 28, 2022 have approved for the payment of 02nd interim dividend of Rs. 1.20/- (60deg/o) per equity share of Rs.2/- each, for the Financial Year 2021-22. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed "May 11, 2022" as "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 18, 2022.28-04-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation28-04-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
PRESS RELEASE28-04-2022